Search Results 911-920 of 17094 for monoclonal antibody

1. A Study of the Safety and Effectiveness of QPI-1002 for the Prevention of Delayed Graft Function in Transplant Recipients from Older Kidney Donors who have Died - Mayo Clinic

   ... monoclonal antibodies per center standard of care. Must be up-to-date on ... Has a positive T- or B-cell flow cross-match AND donor specific anti-HLA antibody ...

2. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   Monoclonal antibodies (anti-CD38 and anti-SLAMF7 antibody) within 4 weeks prior to leukapheresis;; Any other systemic therapy approved for the treatment of ...

3. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

   ... antibody Patients in Expansion Phase, Cohorts 2 and 3; Previously ... Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline ...

4. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

   Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody. ... Participant has received immune therapy (monoclonal antibody therapy, checkpoint inhibitors) within ...

5. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments - Mayo Clinic

   ... antibody, 1 immunomodulatory imide drug (IMiD) ... monoclonal protein, and skin changes) 2 ... antibody-drug conjugates are not excluded) 6. History ...

6. Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis - Mayo Clinic

   Secondary or familial amyloidosis; · Life expectancy of < 3 months; · Symptomatic multiple myeloma; · Hypersensitivities to other monoclonal antibodies; · Known HIV ...

7. A Study of CMB305 and Atezolizumab in Patients with Sarcoma - Mayo Clinic

   ... monoclonal antibodies, fusion proteins, or CHO cell products. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team ...

8. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Monoclonal plasma cells in the bone marrow ≥ 10% at ... Subject has known allergies, hypersensitivity, or intolerance to VELCADE, monoclonal antibodies ...

9. A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, or T-cell Lymphoma - Mayo Clinic

   - Immunotherapy (monoclonal antibodies) =< 4 weeks prior to registration - ... antibody response, and increased numbers of tumor reactive T-cells. VSV-IFNβ ...

10. Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy - Mayo Clinic

    ... antibody at any point prior to registration -CD20-targeted monoclonal antibody (e.g., rituximab, obinutuzumab or biosimilars) =< 4 weeks prior to ...